Upload
tausiq
View
39
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma. Goal Statement. Case #1 . Question . Venous Thromboembolism. Risk Factors for VTE in Patients With Malignancy. VTE Incidence With Thalidomide or Lenalidomide Without Thromboprophylaxis. - PowerPoint PPT Presentation
Citation preview
Optimizing Therapy Through the Prevention and/or Management
of Adverse Events in Multiple Myeloma
Goal Statement
Case #1
Question
Venous Thromboembolism
Risk Factors for VTE in Patients With Malignancy
VTE Incidence With Thalidomide or Lenalidomide Without Thromboprophylaxis
Guideline Recommendations: Prevention of VTE
Guideline Recommendations: Prevention of VTE (cont)
Case #1 (cont)
Question
Bisphosphonate-Related ONJ
BRONJ Incidence
BRONJ Risk Factors
BRONJ Definition
Prevention of BRONJ
Strategies for Preventing BRONJ
Treatment of Patients With BRONJ
Case #2
Case #2 (cont)
Question
Peripheral Neuropathy
TiPN and BiPN
Carfilzomib: PN
Management of PN
Management of PN: TiPN
Management of PN: BiPN
Question
Myelosuppression
Myelosuppression: Bortezomib
Myelosuppression: Lenalidomide
Myelosuppression: Carfilzomib
Question & Answer Session